Recursion Pharmaceuticals, Inc.
RXRX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | 0.46 | -0.06 | 0.32 |
| FCF Yield | -3.77% | -6.28% | -5.15% | -3.26% |
| EV / EBITDA | -11.33 | -9.43 | -10.81 | -17.35 |
| Quality | ||||
| ROIC | -15.06% | -16.15% | -14.32% | -15.54% |
| Gross Margin | -5.54% | -48.04% | -183.62% | 53.69% |
| Cash Conversion Ratio | 0.72 | 0.44 | 0.65 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.47% | 8.91% | 8.70% | 13.81% |
| Free Cash Flow Growth | 40.53% | -14.27% | -92.60% | 29.65% |
| Safety | ||||
| Net Debt / EBITDA | 2.98 | 2.23 | 2.94 | 3.83 |
| Interest Coverage | -367.14 | 0.00 | -303.75 | -177.86 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 15.57 | 178.10 | 828.88 | -9.06 |